New sequential combinations of noninvasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD

Non-alcoholic fatty liver disease (NAFLD), the liver manifestation of the metabolic syndrome linked to obesity and insulin resistance, affects 25% of the general population both in western and developing countries [1]. As in the other causes of chronic liver disease, liver fibrosis is the main determinant of prognosis in NAFLD [2]. The risk of liver-related mortality increases from fibrosis stage 2 and is exponentially higher when transitioning to stage F3 (bridging fibrosis) then F4 (cirrhosis) [2].

Source: Journal of Hepatology - May 14, 2019 Category: Gastroenterology Authors: J érôme Boursier, Maeva Guillaume, Vincent Leroy, Marie Irlès, Marine Roux, Adrien Lannes, Juliette Foucher, Floraine Zuberbuhler, Cyrielle Delabaudière, Justine Barthelon, Sophie Michalak, Jean-Baptiste Hiriart, Jean-Marie Peron, Theophile Gerster, B Source Type: research